Why Ariad Pharmaceuticals (ARIA) Stock Is Down Today

NEW YORK (TheStreet) -- Ariad Pharmaceuticals (ARIA) shares are declining -4.8% to $5.34 on Wednesday after reporting a second quarter net loss of 30 cents per share, 1 cent worse than analysts were expecting, on revenue of $12.1 million that was down 13.6% from the previous year and missed analysts $13.65 million estimates.

The company's chronic myeloid leukemia treatment, Iclusig, was responsible for $11.9 million in net product revenues during the quarter, with U.S. sales reaching $7.9 million and European sales reaching $4 million.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings team rates ARIAD PHARMACEUTICALS INC as a Sell with a ratings score of D-. TheStreet Ratings Team has this to say about their recommendation:

"We rate ARIAD PHARMACEUTICALS INC (ARIA) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally disappointing historical performance in the stock itself."



ARIA ChartARIA data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

After Soaring to $150, Can Incyte Stir Up More Upside?

After Soaring to $150, Can Incyte Stir Up More Upside?

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

The Next Target in Biotech Land

The Next Target in Biotech Land

The Next Target in Biotech Land

The Next Target in Biotech Land

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)